Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis

Figures

• 

  Figure 1. OAC prescription in patients with AF during the whole study period according to different characteristics. Prescription rate of OACs in patients with different characteristics among subgroups at low risk (left panel), intermediate risk (middle panel) and high risk (right panel) of stroke. The prescription rate of OACs was higher in patients with low risk than in those with high risk of stroke. The prescription rate of OACs varied among patients with different characteristics. AF, atrial fibrillation; CKD, chronic kidney disease; NOACs, non-vitamin K antagonist oral anticoagulants; OACs, oral anticoagulants; PCI, percutaneous coronary intervention; TIA, transit ischaemic attack. *The empty bar denotes no patients in this group.

• 

  Figure 2. Impact of insurance coverage on quality of care regarding OAC prescription among patients with AF. Impact of insurance coverage on quality of care regarding OAC prescription among all the patients with AF (left top), patients with low risk of stroke (right top), intermediate risk of stroke (left bottom) and high risk of stroke (right bottom). Insurance coverage for NOACs was significantly associated with an increased prescription rate of NOACs and an enhanced upward trend in NOAC prescription among all the patients with AF. When considering patients’ eligibility for OACs, insurance coverage for NOACs was associated with level increase in OAC prescription among patients with high, intermediate and low risk of stroke, and was associated a slope increase in the secular trend of NOAC prescription only among patients with high risk of stroke. Solid lines indicate the observed prescription rate of OACs; dotted lines indicate the counterfactual prescription rate of OACs without insurance coverage for NOACs. AF, atrial fibrillation; NOACs, non-vitamin K antagonist oral anticoagulants; OACs, oral anticoagulants.